The ability to command a room, have hushed conversations with loved ones, or even something as simple as answering the phone — these are all things Robin Leaper had to learn anew after amyotrophic ...

Australia’s Neurizon Therapeutics, a biotech advancing innovative treatments for neurodegenerative diseases, has reported positive top-line results from the Open-Label Extension (OLE) study of its ...

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that causes the gradual loss of motor neurons in the brain and spinal cord, leading to muscle weakness, paralysis, and ...

Jodi O’Donnell-Ames founded Hope Loves Company to provide support, resources, and community to children affected by ALS.

Neurizon Therapeutics has reported positive topline results from an open-label extension study of its lead candidate NUZ-001 ...

The long-term data supports the drug’s progression into the HEALEY ALS Platform trial, with NUZ-001 dosing set to commence in Q4 2025. This will only begin, however, if the US Food and Drug ...

Yet another biotech is facing a delay from the FDA as the agency reels from intense staffing cuts. | Yet another biotech is ...

Summary: A new study has uncovered why some motor neurons resist degeneration in ALS while others succumb. Researchers found ...

By analyzing millions of messenger RNA molecules (mRNA) during the course of ALS, researchers at Stockholm University, in ...

"MTPA’s Radicava shows long-term benefit in ALS trials" was originally created and published by Clinical Trials Arena, a ...

The ALS therapy ATH-1105 entered the brain and spinal cord at dose-proportional levels in healthy volunteers, and had a good ...

The U.S. Food and Drug Administration has approved the ketamine product, KETARx, for use in surgical pain management.